The Sputnik V COVID-19 vaccine, developed by the Gamaleya Russian National Research Institute of Epidemiology and Microbiology, has demonstrated an efficacy rate of 92%. The confirmation is based on early interim knowledge from the largest phase III, randomized, placebo-controlled clinical trials conducted. in Russia, with the participation of 40,000 volunteers, according to a statement from Gamaleya and the Russian Direct Investment Fund (RDIF). The trials evaluated efficacy in more than 16,000 volunteers who received the vaccine or placebo 21 days after the first injection.
Following a statistical study of 20 shown cases of coronavirus, the cases were split between vaccinated Americans and those who won the placebo, indicating that the Sputnik V vaccine had a 92% efficacy rate after the second dose, he said. In September 2020, Dr. Reddys and the Russian Direct Investment Fund (RDIF), the Russian sovereign wealth fund, have signed a partnership to conduct clinical trials of the Sputnik V vaccine and its distribution in India. As part of the partnership, RDIF will obtain one hundred million doses of vaccine from Dr. Reddys following regulatory approval in India. On August 11, 2020, the Sputnik V vaccine was registered through the Ministry of Health of Russia and became the first registered COVID-19 vaccine in the world based on the human adenoviral vector. In addition, in September, the vaccine was first administered to a volunteer organization in the “red zones” of Russian hospitals.
The participation of another 10,000 vaccinated volunteers representing doctors and other high-risk teams in civilian outdoor use of the vaccine in clinical trials also showed a vaccine efficacy rate of more than 90 percent, the statement added. In trials conducted at 29 Russian medical centers, more than 20,000 volunteers have been vaccinated with the first dose and more than 16,000 volunteers with the first and second doses of the vaccine. In addition, no unforeseen adverse events have been known in the investigation to date. Some of those vaccinated experienced minor short-term adverse effects, such as pain at the injection site, flu syndrome, fever, weakness, fatigue and headache, according to the statement.
Alexander Gintsburg, director of the Gamaleya Center, said that the publication of interim effects from post-registration clinical trials convincingly demonstrating the effectiveness of the Sputnik V vaccine paves the way for mass vaccination in Russia against COVID-19 in the upcoming weeks. Thanks to increased production at new production centers, the Sputnik V vaccine will soon be available to a wider population, he said. “This will break the existing trend and ultimately lead to a reduction in the incidence of COVID-19 infection rates, first in Russia and then globally,” he said. Pfizer Inc and BioNTech SE said on Monday that their candidate vaccine has been shown to be more than 90% effective in preventing COVID-19.
Indian Railways plans to build suburban facilities in Mumbai with 250 new exercises, new terminals and a revamped network. The reform aims to save exercise, transportation conflicts and reorganize 128 stations. A budget of Rs 15,940 crore has been allocated for railway projects in Maharashtra, which will also see the arrival of new technologies to reduce periods between financial years.